Findings show which age groups are seeing the
biggest increases
ATLANTA, Oct. 29,
2024 /PRNewswire/ -- LexisNexis® Risk Solutions, a
leading provider of data and analytics, released new insights on
breast and colon cancer screening and diagnosis trends from 2021 to
2023. As the U.S. Preventive Services Special Task Force (USPSTF)
continues to examine and lower the age recommendations for breast
cancer and colorectal cancer screenings, this analysis explores how
these guidelines are impacting preventive care.
Even though the USPSTF didn't officially lower the age
recommendation for breast cancer screenings from 50 to 40 until
April 2024, mammograms among adults
in their 40s have been trending up for the last three years.
De-identified medical claims data from LexisNexis® MarketView™ show
a 10.3% increase in mammograms for this age group from 2021 to
2023. Additionally, mammograms among people in their 30s saw an
even bigger percent increase, with 12.5% more mammograms in 2023
than in 2021.
The data analysis also revealed an increase in breast cancer
diagnoses with the largest increases being among people in their
30s and people over 70. Breast cancer diagnoses among people in
their 30s increased by 4%, which is twice the percent increase
in breast cancer diagnoses across all ages. Breast cancer diagnoses
among people over 70 increased by 5.7%, representing more than
100,000 additional breast cancer diagnoses.
USPSTF lowered the recommend age for colon cancer screenings
from 50 to 45 in May 2021, and the
data shows this new age group is responding to the updated
guidance. Colonoscopies among people between 45 and 50 years old
increased 90% from 2021 to 2023. Comparatively, colonoscopies among
all other age groups increased by 16%.
Additionally, the analysis examined the latest utilization
trends of at-home, non-invasive colon cancer screening tests,
including stool DNA-based tests and a fecal immunochemical test
(FIT). Overall, these tests are trending down, indicating a
potential pullback from high pandemic-driven utilization. However,
utilization among people in their 40s is up 30.5% for DNA-based
tests and 19.7% for FIT between 2021 and 2023.
"These insights demonstrate the importance of timely and
consistent population health monitoring. Using up-to-date claims
data empowers healthcare organizations to examine policy change,
healthcare delivery trends, and more effectively design programs
that improve engagement and participation in preventive care, such
as cancer screenings," said Diana
Zuskov, associate vice president of healthcare strategy and
innovation at LexisNexis Risk Solutions. "New innovations, such as
non-invasive direct to consumer testing, show promise in improving
the patient experience while also expanding reach and access to
preventive care. Timely data on how patients are impacted by
changing guidelines and healthcare innovation is critical to
removing barriers to care and addressing health disparities among
groups with limited access to care."
Click here to view the complete data analysis.
About LexisNexis Risk Solutions
LexisNexis Risk Solutions harnesses the power of data and advanced
analytics to provide insights that help businesses and governmental
entities reduce risk and improve decisions to benefit people around
the globe. We provide data and technology solutions for a wide
range of industries including insurance, financial services,
healthcare and government. Headquartered in metro Atlanta, Georgia, we have offices throughout
the world and are part of RELX (LSE: REL/NYSE: RELX), a global
provider of information and analytics for professional and business
customers. For more information, please visit
www.risk.lexisnexis.com and www.relx.com.
Media Contact:
Syed Shabbir
Sr. Manager, Corporate Communications
LexisNexis Risk Solutions
816-572-7709
syed.shabbir@lexisnexisrisk.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/new-insights-from-lexisnexis-risk-solutions-highlight-the-latest-trends-for-breast-and-colon-cancer-diagnoses-and-screenings-302290541.html
SOURCE LexisNexis Risk Solutions
